None
EN
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $62.00 at Canaccord Genuity Group
['Jeff Wilder']
Daily Political
Get Travere Therapeutics alerts:Check Out Our Latest Stock Analysis on Travere TherapeuticsTravere Therapeutics Price PerformanceShares of TVTX traded up $0.96 during mid-day trading on Thursday, hitting $56.52.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings data on Monday, May 4th.
Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%.
As a group, equities analysts expect that Travere Therapeutics will post -0.31 earnings per share for the current fiscal year.
Featured StoriesReceive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.